- Treatment of infections due to sensitive organisms when oral therapy is not feasible
- Serious pelvic inflammatory disease
VIAL SIZE |
STERILE WATER for INJECTION REQUIRED |
FINAL CONCENTRATION |
100 mg |
10 mL |
10 mg/mL |
- Solutions diluted in D5W and NS to 0.1-1 mg/mL stable 7 days refrigerated and 96 hours at room temperature.
- Protect from light
- Solutions Compatible: D5W, NS, ringer's solution, ringer's lactate
- Additives/Above Cassette Compatible: no information
- Y-site Compatible: acyclovir, morphine, KCl, dextrose and amino acids,
- Incompatible: lipids, meropenem, heparin, piperacillin/tazobactam (tazocin)
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
SC | NO |
IM | NO |
IV Direct |
NO |
IV Intermittent Infusion | YES Large Volume Pump ONLY. Don't use a minibag smaller than 50 mL Usual dilution: 0.1 - 1 mg/mL Infusion time: 1-4 hours |
IV Continuous Infusion | NO |
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
Pediatric (>8 years):
- Infection: 2-4 mg/kg/day IV divided Q 12-24 hours
- Maximum: 200 mg/day
Adolescent/Adult:
- Infection: 100-200 mg/day IV in 1-2 divided doses
- Pelvic Inflammatory disease: 100 mg IV Q 12 hours x 14 days administered with cefoxitin
- Phlebitis; dilute solutions and infuse slowly
- Avoid extravasation. If extravasation occurs, see Treatment of Infiltrated Vesicant or Irritant Drugs Guidelines on CHEOnet.
- Nausea, diarrhea, anorexia, pseudomembranous colitis
- Discoloration of teeth in children (< 8 years), photosensitivity, blood dyscrasias
- Retardation of skeletal development in infants
- Not recommended for use in children < 8 years (due to associated retardation in skeletal development)
- Contraindicated in severe hepatic impairment
- Photosensitivity reactions may occur; avoid prolonged sun exposure or tanning equipment
- Monitor renal, hepatic and hematologic function